Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

EUCRISA 2% OINTMENT

crisaborole
$10.6810per GM

Strength

20 mg/g

Manufacturer

Pfizer Inc.

NDC

55724021111

Classification

Brand

Dosage Form

OINTMENT

Route

TOPICAL

Last Updated

4/22/2026

Active Ingredients

CRISABOROLE

Approval Type

New Drug (NDA)

FDA Application

NDA207695

On Market Since

1/30/2017

Pharmacological Classes

Phosphodiesterase 4 Inhibitor
Phosphodiesterase 4 Inhibitors

Price History

1W

0.0%

1M

0.0%

3M

+0.0%

6M

-0.0%

1Y

-0.3%

3Y

+8.6%

5Y

+17.2%

All

+18.6%

Generic Alternatives

1 alternative • Same active ingredient

EUCRISA 2% OINTMENT
Brand
55724021121•Pfizer Inc.
$12.6464
+18% more

Related Drugs

Same classification

DALIRESP 250 MCG TABLET
Brand
00310008828•AstraZeneca Pharmaceuticals LP
$14.9826
per EA
DALIRESP 250 MCG TABLET
Brand
00310008839•AstraZeneca Pharmaceuticals LP
$14.9826
per EA
DALIRESP 500 MCG TABLET
Brand
00310009530•AstraZeneca Pharmaceuticals LP
$15.0027
per EA
DALIRESP 500 MCG TABLET
Brand
00310009590•AstraZeneca Pharmaceuticals LP
$15.0027
per EA
ZORYVE 0.15% CREAM
Brand
80610011560•Arcutis Biotherapeutics, Inc.
$15.3893
per GM
ZORYVE 0.3% CREAM
Brand
80610013060•Arcutis Biotherapeutics, Inc.
$15.3897
per GM
ZORYVE 0.3% FOAM
Brand
80610043060•Arcutis Biotherapeutics, Inc.
$15.3897
per GM
OTEZLA 20 MG TABLET
Brand
55513049760•Amgen Inc.
$89.9522
per EA
OTEZLA 30 MG TABLET
Brand
55513013760•Amgen Inc.
$90.6993
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy